Pharmaceutical

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Jan 9, 2024 - 18:00
Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.
Read the original article

Tags:

Previous Article

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

Next Article

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Super DC Vaccine by Shanghai Cell Therapy Group for Sol...

Oct 3, 2023

STAT+: With new study data, Intra-Cellular could expand use of approved mood-disorder treatment

STAT+: With new study data, Intra-Cellular could expand...

Mar 28, 2023

Vaccine experts urge more inclusivity in clinical trials

Vaccine experts urge more inclusivity in clinical trials

Sep 6, 2023